Provided by Tiger Fintech (Singapore) Pte. Ltd.

Foghorn Therapeutics Inc.

6.19
0.0000
Post-market: 6.420.2300+3.72%19:55 EDT
Volume:82.02K
Turnover:502.88K
Market Cap:345.04M
PE:-4.62
High:6.39
Open:6.21
Low:6.00
Close:6.19
Loading ...

Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses

Simply Wall St.
·
28 Feb

Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

Zacks
·
27 Feb

Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock?

Zacks
·
11 Feb

Analysts Predict Up to ~450% Surge for These 2 ‘Strong Buy’ Penny Stocks

TipRanks
·
09 Feb

Techne (TECH) Tops Q2 Earnings and Revenue Estimates

Zacks
·
05 Feb

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

Zacks
·
03 Feb

B. Riley Initiates Foghorn Therapeutics at Buy With $10 Price Target

MT Newswires Live
·
30 Jan

Foghorn Therapeutics Initiated at Buy by B. Riley Securities

Dow Jones
·
30 Jan

Foghorn Therapeutics initiated with a Buy at B. Riley

TIPRANKS
·
30 Jan

Optimistic Outlook on Foghorn Therapeutics Amid Market Opportunities and Strategic Developments

TIPRANKS
·
30 Jan

BRIEF-Foghorn Therapeutics Inc. Files For Mixed Shelf Of Up To $300 Million - SEC Filing

Reuters
·
25 Jan

Foghorn Therapeutics Files $300 Million Mixed Securities Shelf

MT Newswires Live
·
25 Jan

Foghorn Therapeutics files $300M mixed securities shelf

TIPRANKS
·
25 Jan

Foghorn Therapeutics Outlines Year Ahead for Oncology Drug Candidates

MT Newswires Live
·
13 Jan

Foghorn Therapeutics Inc.: Strong Balance Sheet With Cash, Cash Equivalents, and Marketable Securities of $243.8 Mln Provides Cash Runway Into 2027

THOMSON REUTERS
·
13 Jan

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025

THOMSON REUTERS
·
13 Jan

Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know

Zacks
·
10 Jan